Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy. - Wikidata - thesis-toulmin - TriplyDB

Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy.

Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy.

http://www.wikidata.org/entity/Q35102167

about

The role of statins in the setting of HIV infection Atherosclerotic Cardiovascular Disease and Anti-Retroviral Therapy.Inflammation, Immune Activation, and Antiretroviral Therapy in HIV Highly Active Antiretroviral Therapy (HAART)-Related Hypertriglyceridemia Is Associated With Failure of Recovery of CD14lowCD16+ Monocyte Subsets in AIDS Patients.Chronic, not acute, skin-specific inflammation promotes thrombosis in psoriasis murine models Effects of Prednisolone on Disease Progression in Antiretroviral-Untreated HIV Infection: A 2-Year Randomized, Double-Blind Placebo-Controlled Clinical Trial.Plasma CXCL10, sCD163 and sCD14 Levels Have Distinct Associations with Antiretroviral Treatment and Cardiovascular Disease Risk Factors.Plasma Selenium Concentrations Are Sufficient and Associated with Protease Inhibitor Use in Treated HIV-Infected Adults Effects of atorvastatin on biomarkers of immune activation, inflammation, and lipids in virologically suppressed, human immunodeficiency virus-1-infected individuals with low-density lipoprotein cholesterol <130 mg/dL (AIDS Clinical Trials Group Stu Statins to improve cardiovascular outcomes in treated HIV infection.Changes in oxidized lipids drive the improvement in monocyte activation and vascular disease after statin therapy in HIV.Soluble CD163 and monocyte populations in response to antiretroviral therapy and in relationship with neuropsychological testing among HIV-infected children.The Effect of Rosuvastatin on Markers of Immune Activation in Treatment-Naive Human Immunodeficiency Virus-Patients.Immune activation and cardiovascular disease in chronic HIV infection.Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized Therapy SIV/SHIV Infection Triggers Vascular Inflammation, Diminished Expression of Krüppel-like Factor 2 and Endothelial Dysfunction.Effects of 96 Weeks of Rosuvastatin on Bone, Muscle, and Fat in HIV-Infected Adults on Effective Antiretroviral Therapy.Inflammation, immune activation, and cardiovascular disease in HIV.Pathophysiology and management of cardiovascular disease in patients with HIV Antiretroviral therapy in HIV-1-infected individuals with CD4 count below 100 cells/mm3 results in differential recovery of monocyte activation.Does systemic inflammation and immune activation contribute to fracture risk in HIV?Rosuvastatin Decreases Intestinal Fatty Acid Binding Protein (I-FABP), but Does Not Alter Zonulin or Lipopolysaccharide Binding Protein (LBP) Levels, in HIV-Infected Subjects on Antiretroviral Therapy Effect of rosuvastatin on plasma coenzyme Q10 in HIV-infected individuals on antiretroviral therapy.Serum oxidized low-density lipoprotein decreases in response to statin therapy and relates independently to reductions in coronary plaque in patients with HIV.Altered Maturation Status and Possible Immune Exhaustion of CD8 T Lymphocytes in the Peripheral Blood of Patients Presenting With Acute Coronary Syndromes.Epidemiology of ischemic heart disease in HIV.Management of bone mineral density in HIV-infected patients.Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV Infection A Direct Comparison of the Effects of the Antiretroviral Drugs Stavudine, Tenofovir and the Combination Lopinavir/Ritonavir on Bone Metabolism in a Rat Model.Lipid Abnormalities and Inflammation in HIV Inflection.Rosuvastatin slows progression of subclinical atherosclerosis in patients with treated HIV infection.Metabolic Complications and Glucose Metabolism in HIV Infection: A Review of the Evidence.Kaleidoscope of autoimmune diseases in HIV infection.Metabolic and Cardiovascular Complications in HIV/HCV-Co-infected Patients.Strategies to limit immune-activation in HIV patients.Incidental findings on chest computed tomography are common and linked to inflammation in HIV-infected adults.Cardiovascular disease risk among women living with HIV in North America and Europe.Effect of Pericardial Fat Volume and Density on Markers of Insulin Resistance and Inflammation in Patients With Human Immunodeficiency Virus Infection.Cardiovascular risk and dyslipidemia among persons living with HIV: a review.Association of Anisocytosis with Markers of Immune Activation and Exhaustion in Treated HIV.

P2860

Q27027724-5B235D4B-FDA6-4049-89BA-4B6F8CB49E10 Q30248286-7E9BE596-3A7A-435C-80D2-2BF0016E6463 Q33912595-B7875B49-6CCE-4462-B33F-DC5EBEB084E8 Q35857927-3DE92CDF-75FE-4D76-A98B-49B72ADCC8A4 Q35870923-AA02BAF4-1D8D-41BE-9E6F-12DE5FE6C377 Q35904816-AA6712FA-BFB4-424F-88EE-464914AC1436 Q36063953-3C1852BD-733F-4932-B206-D7B68AE80A3A Q36087826-9BC845D9-5E09-4493-9E33-AC2D1F75381E Q36341298-396BF0EF-418A-493C-B76C-B7A4D69C77C8 Q36399904-8006B0BD-3D71-4685-8E81-F12143931F2C Q36436569-6F0F48A0-7154-459C-BF25-BB2257CB7A4D Q36509571-3A540BA3-4CE2-428F-A6A3-B01466D9B32A Q36516798-2F1D8289-13E6-40EC-A52E-A77170851C2E Q36556082-045D372A-E81D-4AA2-AD9F-0C415CFB3301 Q36628396-2BB7717D-35E9-4A78-96C4-9E40ADA467EE Q36745235-A1ED2A1C-019D-4887-9C1B-5F8E683D945F Q36756261-DE49C0E4-A20F-4372-B9C0-6B94D156EF6B Q36957752-B4A6A420-4E3C-46AF-BD69-37A825D09511 Q37038775-B4368CB1-A033-400E-B3BE-1719CD268D11 Q37098066-CCD7FC2D-FDF6-4ABB-A17A-5E49103F6DAB Q37138907-8134E983-972F-47E1-81E6-D5A00F87C501 Q37149855-3A6CE721-A285-406C-8F51-107A15D45581 Q37165704-88AF30EC-33D5-4715-B6C7-6BF7221705DC Q37294964-E6CAF0CF-51E0-42BE-A6B9-49A8CED95C69 Q37365537-7ED528BB-FA7D-43A9-B5C3-CE6AC36339DC Q38629009-4ED71452-BED4-4380-BDF5-50C65FB1A173 Q38711437-91EDA2B2-CBD5-4BC4-86C7-C6F26821F049 Q38749963-D951134E-8580-4D34-8B74-07D7BEE26551 Q38772820-1DCB7AD8-2458-4DCB-8929-053D05B9898F Q38849283-92B126E7-4602-4171-8DC0-D7289CAE1F6A Q38864670-F66DE575-2C80-4CA1-AAA0-557CF8BD010A Q38931905-33288487-0FD6-483D-8F96-88BBC66531CE Q38932786-E60FAF7B-743A-406B-8264-FB9CE56044C3 Q38946641-12CDD320-6D6E-4651-93A3-AAC37F679CB1 Q38985926-1525F883-DA19-4DF1-95E1-CBA93528218A Q39372824-2CE41900-D6CA-4B3C-B318-8DE6BF5627CE Q40074176-EB23496F-5756-47A4-8B71-C9E60BCB1214 Q40077741-30B2CEF5-3D26-40D2-A3D6-D77A81C7C31C Q40100018-173A4AB9-4EFC-4F53-B8A9-91216C3A3EFB Q40132566-DF18E3C6-7DAF-40AA-BD24-B349D4201370

P2860

Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy.

http://www.wikidata.org/entity/Q35102167

description

2015 nî lūn-bûn

@nan

2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Rosuvastatin reduces vascular ...... cts on antiretroviral therapy.

@ast

Rosuvastatin reduces vascular ...... cts on antiretroviral therapy.

@en

type

label

Rosuvastatin reduces vascular ...... cts on antiretroviral therapy.

@ast

Rosuvastatin reduces vascular ...... cts on antiretroviral therapy.

@en

prefLabel

Rosuvastatin reduces vascular ...... cts on antiretroviral therapy.

@ast

Rosuvastatin reduces vascular ...... cts on antiretroviral therapy.

@en

P1433

Q35102167-EB7F2B73-EE10-4BBB-ABD5-B2209B6A8FE1

P1476

Q35102167-E9ADEBB8-63B4-4A6F-9743-2F7586934342

P2093

Q35102167-05E669C7-F3D2-4891-A2B6-229EDF295090

Q35102167-1A1384D6-7EAE-48EE-A82B-4775A9C98036

Q35102167-1B2915F4-1E84-42C7-A51C-CE611777A188

Q35102167-5AFF0D66-3F70-4BAE-A14A-E0EED4DA173B

Q35102167-7B0256F9-8A39-4F23-B1BF-355A7BE928E2

Q35102167-A2538F7C-88D4-44DC-8379-6DA91B3372BD

Q35102167-A884E3C7-B222-45E1-9BB8-E564F626CEB7

Q35102167-AF2ABCD9-E608-44AA-AC91-D4B34CF66F51

Q35102167-F4292C3C-ADC5-4C59-9EC8-0A2BAE435BB9

P2860

Q35102167-027C8906-DFE2-49BE-BD90-CA2819261893

Q35102167-13B7C2C1-A57D-457D-865B-1560CECC695D

Q35102167-14C7D834-0832-42A6-B209-21B922E481FC

Q35102167-18376BD2-9AE1-4879-AB4A-4F3F69212016

Q35102167-1A29E11D-C35E-4161-934D-3AAA191C804E

Q35102167-293BFEC9-F348-4805-9305-49697CEDB8B4

Q35102167-2C7E1C21-5E34-4F8D-AE9A-990DE047A749

Q35102167-2E6BEFB5-6551-4FAE-B4B7-4E84B2C767B2

Q35102167-3CE66059-3C91-40D4-9890-68D1C6FC94A3

Q35102167-3EE08A19-6BB3-4338-8638-F456ED8AD510

P304

Q35102167-8DF1D604-B477-43A5-8050-2F56096935F7

P31

Q35102167-00859138-2A18-4506-91CA-E78BDDF14781

P356

Q35102167-6020FD7D-66CB-43A3-84AB-4066E1C935FD

P407

Q35102167-5E0748D9-1C8C-453E-B439-55C0640D6D72

P433

Q35102167-B7D66747-584E-4384-A03D-67A00C141143

P478

Q35102167-46BCF0BD-DC4F-49B8-BF5B-E1322DB25B0D

P50

Q35102167-EEA86611-F4F5-4EFC-B490-8170E2AC363F

P577

Q35102167-47030111-508C-458D-9700-16FF38B37A83

P698

Q35102167-6AA79AF9-2439-463C-8DDC-EC045352BE8B

P921

Q35102167-96DEFC27-82A0-4536-BDE2-3D02162C989D

P932

Q35102167-9EFF7DB1-4156-41D0-8077-0139BE9A3668

P356

QAI.0000000000000478

P1433

Journal of Acquired Immune Deficiency Syndromes

P1476

Rosuvastatin reduces vascular ...... cts on antiretroviral therapy.

@en

P2093

Brian Clagett

http://www.w3.org/2001/XMLSchema#string

Brian Ferrari

http://www.w3.org/2001/XMLSchema#string

Danielle Labbato

http://www.w3.org/2001/XMLSchema#string

Grace A McComsey

http://www.w3.org/2001/XMLSchema#string

Janet Robinson

http://www.w3.org/2001/XMLSchema#string

Michael M Lederman

http://www.w3.org/2001/XMLSchema#string

Sara M Debanne

http://www.w3.org/2001/XMLSchema#string

Steven Juchnowski

http://www.w3.org/2001/XMLSchema#string

Ying Jiang

http://www.w3.org/2001/XMLSchema#string

P2860

Microbial translocation is a cause of systemic immune activation in chronic HIV infection

Stent thrombosis in randomized clinical trials of drug-eluting stents

Inflammatory and coagulation biomarkers and mortality in patients with HIV infection

Inflammation, atherosclerosis, and coronary artery disease

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

Immunologic predictors of coronary artery calcium progression in a contemporary HIV cohort.

Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation

Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy.

Statin-induced Krüppel-like factor 2 expression in human and mouse T cells reduces inflammatory and pathogenic responses.

Enhanced neointima formation following arterial injury in immune deficient Rag-1-/- mice is attenuated by adoptive transfer of CD8 T cells.

P304

396-404

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAI.0000000000000478

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

68

http://www.w3.org/2001/XMLSchema#string

P50

Nicholas Funderburg

P577

2015-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25514794

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

4334694

http://www.w3.org/2001/XMLSchema#string